The 3rd Annual

AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 12-14, 2024 | **BOSTON, USA**

The leading event globally focused solely on AI in Drug Discovery

KEY SPEAKERS

Jackie Hunter
CEO

Peter Clark
VP Computational Drug Design

Ashwini Ghogare
CEO & Head of AI & Automation in Drug Discovery

Daniyal Hussain
Executive Director of Technology Business Development

Robert Goodnow
Head of Drug Discovery Science

Yu Qiu
Head of AI Innovation - Antibody Digital Biologics Platform

Pertina Kamya
Global Head of AI Platforms

Hayley Donnella
Director of Computational Oncology

ACCELERATE YOUR PIPELINE, SAVE MILLIONS IN R&D

Gain insights from leaders and use cases from Sanofi and **Insilico Medicine** to avoid **pitfalls** and understand real-world successes and failures

ENHANCE AI CAPABILITIES WITH LATEST INNOVATIONS

Discover the latest advances in revolutionary AI for drug discovery and access pioneering applications and technologies to shape your internal capabilities

ELEVATE YOUR STARTUP'S MARKET ACCESS & INVESTMENT PROFILE

Capture attention of investors and boost your market profile by showcasing your innovation at our Tech Test Lab

OPTIMIZE AI/ML INTEGRATION

Strengthen your collaborative network to form strategic partnerships, connect with industry leaders and researchers and learn from top industry pioneers and KOLs

WORKSHOP PARTNER: QIAGEN

REGISTER NOW

Kisaco Research

THE AI EFFECT: ENHANCING EFFICIENCY AND REDUCING COSTS IN DRUG DISCOVERY



WHERE THE AI & PHARMA INDUSTRIES UNITE

AI has saved drug developers 40% in costs through optimizing AI in the discovery stages. At the start of 2024, 95% of pharma companies are using AI in discovery phases and as drug development innovations soar, failure to implement AI-driven solutions is not only a missed opportunity, but a costly oversight. Make sure you are leveraging new AI technologies to give you a competitive advantage in the race to get a drug to market.

Join over **300** leaders from AI and pharma to shape drug discovery's future by spotlighting innovative approaches, **leveraging AI tools**, and **optimizing R&D through strategic collaborations** for faster, more effective drug discovery.

PREVIOUS ATTENDEES

abbvie, AMGEN, AstraZeneca, Bayer, Benevolent AI, Boehringer Ingelheim, Novartis, sanofi, Bristol Myers Squibb, Lilly, EMD Serono, Exscientia, FDA, Google, Pfizer, Takeda, GSK, IBM, Insilico Medicine, janssen, MERCK, moderna, Recursion, ucb

AUDIENCE BREAKDOWN

35%	20%	10%	5%	15%	15%
PHARMA	BIOTECH	ACADEMIC	INVESTORS	AI DISCOVERY PLATFORMS	VENDORS/ SERVICE

YOUR 2024 JOURNEY

SPLIT CONTENT - BIOLOGY V CHEMISTRY

- Customize your conference experience by selecting sessions tailored to your research focus.

CEO & FOUNDERS BREAKFAST

- Network with industry leaders to drive innovation and growth for your organization.

INVESTOR MEET AND GREET

- Connect with investors seeking AI-driven initiatives in drug discovery, and explore funding options aligned with your vision and goals.

PRE-DAY WORKSHOP WITH QIAGEN

- Delve into Qiagen's AI derived biomedical knowledge base used to accelerate drug discovery.

REGISTER YOUR INTEREST

WOMEN IN AI LUNCH

- Celebrate diversity and inclusion in AI and pharmaceuticals, and gain insights from inspiring speakers focused on empowering women in the field.

APPLY

INNOVATION INCUBATOR

- Showcase your pioneering technologies and innovations to our entire delegation, and panel of expert investors as they provide valuable feedback on your product.

APPLY

2024 ADVISORY BOARD

The AI-Driven Drug Discovery Summit Advisory Board guides our events and content, ensuring they align with our mission. With their objective and collaborative approach, they maintain an industry-driven platform for stakeholders to share, network, and build partnerships.

Clement Chatelain
Head Human Genetics & Genomics

Lingling Shen
Associate Director Data Science Discovery Sciences

Elena Diez Cecilia
Senior Director, External Innovation

Alla Bushoy
Engineering Team Lead

Ari Allyn-Feuer
Director, AI/ML Product

Claire Zhao
Associate Director of AI/ML & Quantitative & Digital Sciences

LOOK WHO'S TALKING

Robert Goodnow
Head of Drug Discovery Sciences
TAKEDA

Peter Clark
VP Computational Drug Design
NOVO NORDISK

Jacob Berlin
CEO
TERRAY THERAPEUTICS

Mark Adams
Venture Capital Partner
TWO BEAR CAPITAL

Lu Zhang
Founder & Managing Partner
FUSION FUND

Ari Allyn Feuer
Director AI Product
GSK

Ashwini Ghogare
CEO & Head of AI & Automation in Drug Discovery
MILLIPORESIGMA

Zachary Webel
Data Scientist & Applied Mathematician
CARRIER

Lena Dolgikh
Head of Computational Chemistry
MONTE ROSA THERAPEUTICS

Ed Addison
Acting CEO
CLOUD PHARMACEUTICALS

Zhiyong (Sean) Xie
VP & Head of AI & Data Science
XELLARBIO

Arvind Rao
Professor
UNIVERSITY OF MICHIGAN

Zoran Krunic
Senior Manager Data Science
AMGEN

Yang-ming Zhu
SVP Head of Engineering (AI & ML)
SUPERLUMINAL

Hiroyoshi Toyoshiba
CTO
FRONTEO

Simon Beaulah
SVP Healthcare & Head of US
PRECISION HEALTH

Pertina Kamya
Global Head of AI Platforms **INSILICO MEDICINE**

Rohit Arora
Innovation Lead
NOVO NORDISK

Ethan Pickering
Head of Data Science & Machine Learning Research **BAYER**

Monica Wang
Head of Biologics & Novel Modality Discovery Capabilities & Products, Scientific Informatics
TAKEDA

Claire Leurent
Managing Director
ABBVIE VENTURES

LOOK WHO'S TALKING

Karen Akinsanya
President R&D
SCHRODINGER

Sriram Chandrasekaran
Associate Professor, Biomedical Engineering
UNIVERSITY OF MICHIGAN



Mani Foroohar
Senior Managing Director Biotechnology Analyst
LEERINK

Nevin Gerek Ince
Director Data & Solutions Engineering
NOVO NORDISK

Soujanya Bhumkar
Co-founder
GENIE LIFESCIENCES

Julian Hess
Computational Scientist
BROAD INSTITUTE OF MIT & HARVARD

Charles O'Donnell
Vice President, Head of Computational Genomics & Data Sciences
OMEGA THERAPEUTICS



Hayley Donnella
Director of Computational Oncology
RECURSION

Daniyal Hussain
Executive Director of Technology Business Development
GSK

Yu Qiu
Head of AI Innovation - Antibody Digital Biologics Platform
SANOFI

Serhat Tetikol
Associate Director
BRISTOL MYERS SQUIBB

Jackie Hunter
CEO
OI PHARMA PARTNERS

Chirag Sacher
Director Portfolio Innovation **NOVARTIS**

Lauris Kemp
Partner and Patent Attorney **HGF**

Peter McLean
Director Data Science
RECURSION

Elena Diez Cecilia
Senior Director External Innovations
JANSSEN R&D

Xia Ning
Professor
OHIO STATE UNIVERSITY

Aiden Aceves
VP
INSIGHT PARTNERS

PRE-DAY WORKSHOP WITH QIAGEN

NOVEMBER 12 – BOSTON, MA

BIOMEDICAL KNOWLEDGE GRAPH WORKSHOP

Accelerating drug discovery with high-quality data

Kickstart your AI Driven Drug Discovery Summit experience with our pre-day workshop hosted by Qiagen. Designed specifically for pharmaceutical companies, this workshop will delve into Qiagen's cutting-edge AI-derived biomedical knowledge base, a powerful tool that is revolutionizing drug discovery.

QIAGEN

REGISTER YOUR INTEREST

WHY ATTEND?

- **Innovative Insights:**
  Gain a deeper understanding of how to leverage AI and high-quality data to streamline your drug discovery pipeline.
- **Expert Guidance:**
  Benefit from Qiagen's extensive experience and expertise in integrating AI into biomedical research.
- **Strategic Advantages:**
  Discover strategies and tools that can provide a competitive edge in the rapidly evolving pharmaceutical landscape.

WHAT TO EXPECT:

- **Deep Dive into Qiagen's Knowledge Graph:**
  Explore the advanced methodologies and AI technologies Qiagen employs to create a comprehensive biomedical knowledge graph.
- **Hands-On Sessions:**
  Participate in interactive sessions where you can see firsthand how high-quality data accelerates drug discovery and improves outcomes.
- **Case Studies:**
  Learn from real-world examples and success stories of how Qiagen's knowledge base has been effectively utilized in the drug discovery process.
- **Networking Opportunities:**
  Connect with industry leaders, experts, and peers to discuss the latest trends, challenges, and innovations in AI-driven drug discovery.

DAY 1 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 13 – BOSTON, MA

8-8.50am

Registration

8.50-9am

Opening Remarks

9-9.45am

Executive Panel - Recent Advances and Future Perspectives for AI in Drug Discovery

- Pursuing Artificial Intelligence, Machine Learning and Natural Language Processing technology to enable medicinal chemistry and drug discovery.
- Gain a comprehensive understanding on the hype around Generative AI. Discuss recent advancements and successes, challenges and limitations, future outlook and emerging trends to make informed decisions about gen AI's applications.
- Layout remaining challenges and limitations of current methods with a view to possible solutions and potential future directions of AI-assisted drug discovery and design.

ROBERT GOODNOW, Head Drug Discovery Sciences, **Takeda**
ROHIT ARORA, Innovation Lead, **Novo Nordisk**
PETER CLARK, VP Computational Drug Design, **Novo Nordisk**
ASHWINI GHOGARE, CEO & Head of AI & Automation in Drug Discovery, **MilliporeSigma**

9.45-10.15am

PRODUCER PICK

How Can Generative AI Change the State Of the Art? Navigating Generative AI In Drug Discovery & Data Analysis

- With the rise of ChatGPT, interest in the applications of the technology in drug discovery is on the upswing. What should you consider when building a business case for the use of generative technologies to speed up drug discovery?
- What procedures should be considered when putting generative AI into practice – including prompt-based prototyping, data generation, programmatic data labelling & model selection?

JACOB BERLIN, CEO, **Terray Therapeutics**

10.15-11am

Investment Trends in AI-Driven Drug Discovery

- Exploring the current landscape of AI investment in pharmaceutical R&D and gain insights into prioritization of technologies to position your platform development strategies effectively.
- Understand opportunities and challenges for AI-startups in drug discovery to refine platform development strategies and address potential obstacles.
- Investor perspectives – what venture capitalists look for in AI-driven drug discovery companies to tailor your business development strategy to align with investor expectations.

MARK ADAMS, Venture Capital Partner, **Two Bear Capital**
LU ZHANG, Founder & Managing Partner, **Fusion Fund**
MANI FOROOHAR, Senior Managing Director Biotechnology Analyst, **Leerink**
AIDEN ACEVES, VP, **Insight Partners**

DAY 1 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 13 – BOSTON, MA

11-11.45am
Networking Break

BIOLOGY TRACK
Target Discovery & Identification

11.45-12.15pm

Highlighting Innovations in Machine Learning for Target Identification
- *Grasping how computational approaches can leverage diverse omics datasets at scale to make in-silico target predictions.*
- *Recent advances in ML including natural language processing (NLP), for more powerful data mining of target association knowledge.*
- *Understanding the opportunities and challenges in using deep learning methods for the identification of potential therapeutic targets, including modelling genetic splicing variation.*

MONICA WANG, Head of Biologics and Novel Modality Discovery Capabilities and Products & Scientific Informatics, **Takeda**

12.15-12.45pm **PRODUCER PICK**

Is there any open space left in Target Identification & AI drug discovery?
- *A new approach that leverages the AI engine "KIBIT" to unearth hidden connections unpublished in research papers promises to boost the search for novel drugs.*
- *Overcoming human bias with two theorems（Distributional hypothesis and spreading activation）*
- *Analysis methods using the gene networks drawn by KIBIT are excellent at uncovering unknown relationships between disease and genes with few or no hits in PubMed and generating hypotheses of novel targets.*

HIROYOSHI TOYOSHIBA, CTO, **FRONTEO**

CHEMISTRY TRACK
Molecular Design & Optimization

11.45-12.15pm

AI-Driven Molecular Glue Discovery and Optimization
- *HeadlongTM E3 Ligase virtual screening pipeline to identify new scaffolds.*
- *COSMOSTM neosurface-small molecule method to assess molecular glue degrader selectivity and diversity.*
- *FLASHTM Virtual MGD pipeline to enable virtual screening, hit discovery and quick hit expansion.*
- *GlueAIDTM in-house suite of ADME machine-learning models*

LENA DOLGIKH, Head of Computational Chemistry, **Monte Rosa Therapeutics**

12.15-12.45pm **PRODUCER PICK**

AI/ML for molecular design and optimization
- *Understand how AI/ML technologies facilitate the design of novel molecules with desired properties.*
- *Discover AI/ML methods to optimize molecular structures for improved efficacy and safety.*
- *Learn from case studies showcasing successful implementations of AI/ML in molecular design and optimization.*

PETER CLARK, VP Computational Drug Design, **Novo Nordisk**

DAY 1 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 13 – BOSTON, MA

12.45-1.15pm

AI-Driven Approaches for Disease Pathway Analysis and Target Identification

- *Integrating AI, Machine Learning and systems Biology Approaches and understand best practices for data integration, algorithm selection, model validation, and interpretation of results.*
- *Explore how AI-driven approaches leverage advanced algorithms to analyse omics data, identify molecular pathways implicated in disease pathology and reveal underlying mechanisms driving disease progression.*
- *Understand how AI-driven pathway analysis expedites the identification and validation of novel therapeutic targets.*

ARI ALLYN-FEUER, Director AI Product, **GSK**

12.45-1.15pm

AI-Based Language Models Powering Drug Discovery

- *Highlight opportunities for AI-powered language models (LMs) in target identification, clinical design, regulatory decision-making, and pharmacovigilance.*
- *Positioning AI-powered language models through a 'fit for purpose' selection.*

YU QIU, Head of AI Innovation – Antibody, Digital Biologics Platform, **Sanofi**

1.15-2.30pm

Lunch

Disease Modelling & Precision Medicine

2.30-3pm

Precision Medicine for Complex Chronic Disease: A New Era of Biopharma Innovation

- *A novel AI-driven precision medicine approach to analyze multimodal patient data to stratify chronic disease populations based on common disease mechanisms, thereby de-risking biopharma innovation and increasing success probabilities in developing therapies for diseases affecting billions.*
- *Highlight how this approach provides a deeper mechanistic understanding of disease biology, enabling drug developers to leverage novel causal disease biology insights to select the right target, indication, and patients for programs, ultimately leading to the development of life-changing therapies for complex diseases.*

SIMON BEAULAH, SVP Healthcare & Head of US, **PrecisionLife**

High Performance Computing & Process Optimization

2.30-3pm

Formula For Success in Industrializing Drug Discovery: Data, Models And Compute

- *Understand the role of high-quality data and advanced AI models in optimizing drug discovery processes.*
- *Discover how scalable computing solutions enhance efficiency and speed in drug discovery.*
- *Learn the importance of combining data, models, and compute power, and the role of strategic partnerships in streamlining drug discovery.*

HAYLEY DONNELLA, Director Computational Oncology, **Recursion**

DAY 1 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 13 – BOSTON, MA

3-3.30pm

Integration Of Multi-Omic Data for Precision Medicine

- *Using AI/ML to generate integrative models for multi-omics.*
- *Developing a uniform end-to-end framework for efficient processing, integration, and analysis of multi-omics data.*
- *Outlining steps to standardize and harmonize data from high-throughput technologies that exist in a variety of different formats.*
- *Discussing the possible implications of such an advancement, and how an integrative approach can help build predictive models of risk, treatment response, and clinical outcomes (in addition to enabling disease subtyping and classification, and biomarker identification).*

TEJASWI IYYANKI, *Principal Scientist*, **Sanofi**

3.30-4pm

Precision Therapeutics Using AI-Powered Endotyping

- *Understand the concept of endotyping and how AI can identify precise patient subgroups for targeted therapies.*
- *Discover how AI-driven endotyping enhances the development of personalized and effective treatment plans.*
- *Learn from case studies demonstrating the successful use of AI-powered endotyping in precision medicine.*

SOUJANYA BHUMKAR, Co-founder, **Gen1e Lifesciences**

3-3.30pm

Leveraging High-Performance Computing and Process Optimization

- *Role of HPC in conducting large-scale molecular simulation, such as molecular dynamics simulations and quantum mechanical calculations to show molecular interactions and inform drug design.*
- *Discuss scalability, efficiency, and cost-effectiveness of HPC architectures and algorithms, including cloud computing, GPU-accelerated computing and distributed computing paradigms.*

3.30-4pm

Advancing Clinical Trials with Quantum Computing and AI: The Convergence

- *Explore the integration of quantum computing and AI, focusing on their combined potential to enhance drug discovery and personalized medicine.*
- *Understand the transformative impact of AI in patient recruitment, data analysis, and trial design, supplemented by examples of successful AI-driven clinical trials.*
- *Discuss the future outlook, emerging trends, and regulatory considerations, alongside strategies to overcome technical and ethical challenges in integrating quantum computing and AI into clinical trials.*

ZORAN KRUNIC, Senior Manager Data Science, **Amgen**

DAY 1 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 13 – BOSTON, MA

4-4.30pm

Networking Break

4.30-5pm

Navigating the IP landscape in AI-Driven Drug Discovery

- Overview of key legal and ethical considerations related to AI applications in drug discovery.
- Intellectual property protection, data privacy, and regulatory compliance issues.
- Guidance on navigating legal challenges and mitigating risks in AI-driven research and development.

LAURIS KEMP, *Partner & Patent Attorney,* **HGF**

5-5.30pm

Panel - AI in Clinical Trials

Understand how AI tools like HINT, SPOT, and Trial Pathfinder revolutionize trial design, patient recruitment, and data management to reduce costs and timelines.
Learn to address AI biases, ensure data privacy, and comply with evolving FDA guidelines for ethical AI deployment in clinical trials.
Gain insights into future AI trends, the potential for decentralized trials, and the importance of cross-industry collaboration to standardize AI applications and develop best practices.

CHIRAG SACHER, *Director Portfolio Innovation,* **Novartis**

5.30-6pm

Optimizing AI Partnerships with Pharma

- How pharma evaluates new AI technologies.
- How diligence is typically conducted.
- Identify critical success factors for pharma partnerships.

DANIYAL HUSSAIN, *Executive Director of Technology & Business Development,* **GSK**

6 - 7pm

Networking Drinks

END OF DAY 1

DAY 2 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 14 – BOSTON, MA

8-9am

CEO & Founders Breakfast

9-10am

PRODUCER PICK

Innovation Incubator

This session provides the unique opportunity to listen to, and engage with, some of the most innovative AI Drug Discovery start-ups globally. Focusing exclusively on early-stage funding, six startups picked by our esteemed selection committee will take to the stage in front of 100+ potential partners. Through a series of rapid-fire presentations, these pioneers will demonstrate their vision of the future of drug discovery, and how their product, technology, or service fits into it.

10-10.30am

How Can AI Be a Meaningful End-To-End Solution For Drug Development

- Discuss how AI methods can be integrated into an end-to-end meaningful solution. How AI technologies, coupled with automation, can streamline processes, enhance efficiency, and enable faster decision making.
- Explore the potential of hybrid models that combine the capabilities of people & machines.
- Understand how we can get both working together cohesively.

ED ADDISON, Acting CEO, **Cloud Pharmaceuticals**
ELENA DIEZ CECILIA, Senior Director External Innovations, **Janssen R&D**
CHARLES O'DONNEL, VP Head of Computational Genomics and Data Sciences, **Omega Therapeutics**

10.30-11am

How AI can Accelerate the Development of Personalized Treatment for Patients

-The effect of the microbiome on drug responses especially in oncology is now well known
- Predicting microbiome-drug interactions across populations, individuals and tumour subtypes can enable precision medicine development
- AI can also be used later in development to enable better patient selection and shorten trial timelines

JACKIE HUNTER, CEO, **OI Pharma Partners**

11-11.30am

Networking Break

DAY 2 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 14 – BOSTON, MA

BIOLOGY TRACK

Hit-Identification & Structure Based Drug Design

11.30-12pm

Harnessing Protein Structure Insights for Hit Identification and Drug Design

- *Integration of machine learning models with structural biology techniques to enhance the efficiency of protein structure determination and ligand binding prediction.*
- *Application of AI-driven virtual screening methods to efficiently screen large compound libraries against oncogenic protein targets.*

SERHAT TETIKOL, Associate Director, **Bristol Myers Squibb**

12-12.30pm

Structure-based Drug Design and Molecular Modelling Techniques

- *Overview of machine learning approaches for molecular docking, enabling efficient screening of compound libraries against protein targets to identify potential drug candidates.*
- *Examine AI-based models for predicting binding affinities between ligands and target proteins, enhancing selections and optimization of lead compounds in drug discovery pipelines.*

ARVIND RAO, Professor, **University of Michigan**

12.30-1pm

Accelerating Genomic and Product Design from Bio-Informed Graph Neural Networks to Disease Resistance-Preserving Loss Functions

- *Embedding Biological Information into AI architectures can substantially boost predictive performance*
- *Loss functions attuned to rarity can help uncover disease resistance*
- *Active learning can accelerate genomic design with purposeful exploration*
- *Large Language Models can refine gene editing targets*

ETHAN PICKERING, Head of Data Science and Machine Learning Research, **Bayer**

CHEMISTRY TRACK

Cheminformatics & Virtual Screening

11.30-12pm

AI-powered high-throughput screening and virtual compound screening

- *Understanding how AI can be deployed to handle the recent explosion of chemical libraries and increase the efficiency of virtual screening approaches.*
- *Combination of computer vision and high content imaging to better understand drug action and mechanism*
- *The role of organ-on-a-chip in drug screening and the AI methods on the data analysis.*

ZHIYONG XIE, VP & Head of AI and Data Science, **Xellarbio**

12-12.30pm

Reshaping Early Drug Development: Leveraging AI/ML and Omic-Scale Cellular Profiling

- *Present some of the challenges associated with transitioning a univariate-dominated drug discovery & development process into a high-dimensional search problem.*
- *Highlight the role of data-generation and experiment design in large-scale ML system development.*
- *Discuss real-world applications of these strategies, including in vitro profiling of chemistry.*

PETER MCLEAN, Director Data Science, **Recursion**

12.30-1pm

Optimizing High Content Screening Imaging Analysis for Target Identification: Data Management Solutions

- *Understand the integration of platforms for seamless management from data capture to analysis in high content screening.*
- *Learn strategies to improve data quality and processing speed for high content screening imaging analysis.*
- *Explore real-world case studies to apply optimized data management solutions effectively in identifying molecular targets.*

NEVIN GEREK INCE, Director Data & Solutions Engineering, **Novo Nordisk**

1-2pm

Lunch & Women in AIDDD Lunch

DAY 2 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 14 – BOSTON, MA

Data Management & Drug Repositioning

2-2.30pm

Harnessing Big Data – Strategies for Effective Data Management in AI-Driven Drug Discovery
- *Evaluate strategies for handling and integrating diverse datasets, including omics data, clinical data, and real-world data to support decision making.*
- *Optimize data utilization to enhance research capabilities and accelerate discovery of novel therapeutics.*

JULIAN HESS, Computational Scientist, **Broad Institute of MIT and Harvard**

2.30-3pm

Generative AI's Role in Next-Generation Drug Development
- *Learn about generative AI and explore frameworks like diffusion models, deep reinforcement learning, and auto-encoder-based deep learning.*
- *Discover how generative AI can design and optimize new small molecules in 2D and 3D formats, surpassing traditional methods.*
- *Understand how generative AI identifies retrosynthesis paths for molecule synthesis, enhancing efficiency in drug development.*

XIA NING, Professor, **Ohio State University**

3.30-4PM

Generative AI Fundamentals: A Optimized Approach to Compact Transformer Models for Predicting Viral Evolution

ZACHARY WEBEL, Independent Researcher

Toxicology & Bioactivity

2-2.30pm

Optimizing Potency vs Toxicity using AI Models
- *Harnessing AI algorithms to predict toxicity by analysing chemical structures, protein sequences and multi omics data.*
- *Modeling the tradeoffs in optimizing potency vs toxicity using mechanistic deep-learning models*
- *Interpreting AI models to understand interaction mechanisms (molecular interactions and biological pathways) driving potency and toxicity of drug combinations.*

SRIRAM CHANDRASEKARAN, Associate Professor Biomedical Engineering, **University of Michigan**

2.30-3pm

Applying AI/ML in Drug Discovery
- *How ADME/Tox predictive models can be used early and often to profile potential compound risks and liabilities.*
- *How a predictive docking approach vastly improves the virtual screening throughput.*
- *How GenAI is integrated in screening, hit expansion and lead optimization.*

YANG-MING ZHU, *SVP Head of Engineering,* **Superluminal**

3.30-4PM

TBC

.

4-4.30pm

Networking Break & Poster Presentations

DAY 2 AI DRIVEN DRUG DISCOVERY SUMMIT

NOVEMBER 14 – BOSTON, MA

4.30-5pm

Case studies on leveraging AI from Target Discovery to the Clinic
- Learn from real examples of where AI has made a difference to the drug discovery and development space.
- Understand how and when AI was leveraged in the drug discovery value chain.

PETRINA KAMYA, *President Insilico Medicine Canada and Global Head of AI Platforms,* **Insilico Medicine**

5pm

Close of Conference



PARTNER WITH US

Become the solution to the industry's challenges by showcasing your value in a new light. Elevate your reputation and foster valuable connections, leading to a multitude of opportunities for meaningful partnerships.

THOUGHT LEADERSHIP
Keynotes, Panel Contributor, Chairing & Moderator, Customer & Tech Insight Sessions, Webinars, Industry & Research Reports, White Papers

NETWORKING
1:1 Meetings, Exhibition Booth, Drinks Reception, Breakfast Briefing, Coffee Sponsor, Lunch Sponsor

BRANDING
Signage, Digital Marketing Campaigns, Social Media, Exhibition Booth, Lanyards, Registration Sponsor, Event Bags

LEAD GENERATION
Partnering Platform, Content Syndication, Webinars, Reports and White Papers, On-Site Competitions

FIND OUT MORE

2024 PARTNERS

LEAD PARTNER	GOLD PARTNER	SILVER PARTNERS	BRONZE PARTNER	WORKSHOP PARTNER
MilliporeSigma	FRONTEO	HGF, VULTR	QCWARE	QIAGEN

CONTACT THE TEAM

Ryan Sanderson
Partnerships Director
ryan.sanderson@kisacoresearch.com

Charles Sheppard
Sponsorship Director, Healthcare and Life Sciences
charles.sheppard@kisacoresearch.com

Thomas Carter
Commercial Partnerships Manager
thomas.carter@kisacoresearch.com

PRICING

www.aidrivendrugdevelopment.com
+44 (0) 203 696 2920
events@kisacoresearch.com

Kisaco Research

ACADEMICS

Book by August 23

- *A Teacher, Professor, Researcher or Scholar at a University or Higher Education Institute, registration to be completed with academic email address*
- *An organization with NPO or Charitable Status*

$ 799

REGISTER

STARTUP COMPANIES

Book by August 23

- *Pre-series A funding*

$ 1,199

REGISTER

PHARMA/BIOTECHS

Book by August 23

- *Must be currently developing an in-house drug candidate with a publicly available pipeline*
- *Must not offer paid-for or partnering services to drug developers.*
- *Biotechs must have their own internal pipeline*

$ 1,649

REGISTER

SERVICE PROVIDERS

- *Offering paid-for products and/or partnering services, including but not limited to:*
  - *Consultants*
  - *CROs*
  - *CDMOs*
  - *Discovery Tool Providers*
  - *Equipment Manufacturers*

$ 3,499

REGISTER

TERMS AND CONDITIONS: *Team discounts are only valid on industry rate and not in conjuction with any other offer or promotion. a $49 processing fee will apply to any invoices requested. All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer. Please review our cancellation policy.*
Questions? *Please email events@kisacoresearch.com*

VENUE

ALOFT BOSTON SEAPORT DISTRICT HOTEL
401-403 D STREET
BOSTON, MASSACHUSETTS
02210

INTERESTED IN JOINING US?

Niamh Middlemass
Conference Producer
niamh.middlemass@kisacoresearch.com

Charles Sheppard
Sponsorship Director, Healthcare and Life Sciences
charles.sheppard@kisacoresearch.com

Libby Maloney
Senior Marketing Executive
libby.maloney@kisacoresearch.com

Ryan Sanderson
Partnerships Director
ryan.sanderson@kisacoresearch.com

Thomas Carter
Commercial Partnerships Manager
thomas.carter@kisacoresearch.com